The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
|Videos|July 14, 2016
Dr. Martin Reck on Docetaxel/Ramucirumab in NSCLC
Author(s)Martin Reck, MD
Advertisement
Martin Reck, MD, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, discuses the REVEL trial, a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer (NSCLC).
A significant improvement in overall survival in favor of the combination of docetaxel with ramucirumab, says Reck. An improvement in progression-free survival (PFS) and response rate was also observed.
This important in efficacy was seen independent from histology. An additional analysis was performed on patients who were chemotherapy refractory patients. An additional benefit was seen in this poor prognostic group, said Reck.
Advertisement
Related to this article
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
5